1. Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer
   Yujiro Naito et al, 2017, Medicine CrossRef
2. Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer
   Hajime Oi et al, 2022, Medicine CrossRef
3. Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer
   Fengchun Mu et al, 2023, Future Oncology CrossRef
4. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
   Francesco Gelsomino et al, 2020, British Journal of Cancer CrossRef
5. Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer
   Zenta Seto et al, 2021, Tumori Journal CrossRef
6. Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
   Rui Wan et al, 2023, Therapeutic Advances in Medical Oncology CrossRef
7. A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer
   Xin-shuai Wang et al, 2017, Acta Pharmacologica Sinica CrossRef
8. Albumin nanoparticles with synergistic antitumor efficacy against metastatic lung cancers
   Bomi Kim et al, 2017, Colloids and Surfaces B: Biointerfaces CrossRef